Table 2.
Characteristics of the study population within quartiles of GIP plasma concentrations in MDC-CC
| Characteristic | Total | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|---|
| No. of participants | 3479 | 871 | 870 | 867 | 871 |
| Fasting GIP | |||||
| Age, years | 72.4 ± 5.6 | 71.6 ± 5.4 | 72.5 ± 5.6 | 72.8 ± 5.6 | 72.9 ± 5.6 |
| Female sex | 2184 (59.1) | 523 (60) | 503 (57.9) | 494 (57.1) | 522 (59.9) |
| BMI, kg/m2 | 26.9 ± 4.4 | 26.4 ± 3.9 | 26.6 ± 4.0 | 26.8 ± 4.4 | 27.8 ± 5.0 |
| Fasting GIP, pmol/l | 41.2 (30.4–56.8) | 24.5 (20.3–27.6) | 35.9 (33.2–38.3) | 47.6 (44.4–51.5) | 72.9 (63.3–89.3) |
| Fasting insulin, pmol/l | 53.5 (37.5–77.1) | 47.9 (34.7–66.0) | 50.0 (35.4–72.2) | 54.2 (38.9–77.1) | 65.3 (44.4–93.1) |
| FPG, mmol/l | 5.9 (5.4–6.5) | 5.8 (5.3–6.3) | 5.8 (5.4–6.4) | 5.9 (5.4–6.5) | 6.1 (5.5–6.8) |
| SBP, mmHg | 143 ± 18 | 141 ± 17 | 144 ± 19 | 144 ± 18 | 144 ± 20 |
| LDL-cholesterol, mmol/l | 3.3 (2.6–3.9) | 3.4 (2.8–4.0) | 3.3 (2.7–3.9) | 3.2 (2.6–3.9) | 3.1 (2.4–3.8) |
| HDL-cholesterol, mmol/l | 1.4 (1.1–1.7) | 1.4 (1.1–1.7) | 1.4 (1.1–1.7) | 1.4 (1.1–1.7) | 1.3 (1.0–1.6) |
| Diabetes | 170 (4.9) | 37 (4.3) | 42 (4.8) | 45 (5.1) | 46 (5.2) |
| No. of events (total mortality) | 346 (10.0) | 60 (6.9) | 74 (8.5) | 88 (10.2) | 124 (14.2) |
| GIPR rs1800437, MAF | 0.22 | 0.27 | 0.21 | 0.21 | 0.20 |
| Post-challenge GIP | |||||
| No. of participants | 3070 | 768 | 766 | 769 | 767 |
| Age, years | 72.4 ± 5.6 | 71.1 ± 5.6 | 72.0 ± 5.3 | 72.8 ± 5.6 | 73.7 ± 5.5 |
| Female sex | 1830 (59.6) | 355 (46.2) | 425 (55.5) | 488 (63.5) | 562 (73.3) |
| BMI, kg/m2 | 26.6 ± 4.2 | 27.1 ± 4.2 | 26.4 ± 3.9 | 26.5 ± 4.0 | 26.4 ± 4.4 |
| Post-challenge GIP, pmol/l | 222.7 (163.2–293.8) | 129.7 (106.4–147.1) | 193.0 (178.1–207.0) | 253.7 (237.3–272.4) | 356.8 (321.0–414.1) |
| Post-challenge insulin, pmol/l | 277.0 (179.9–441.0) | 257.6 (171.5–400.7) | 266.7 (166.0–427.8) | 273.6 (189.6–441.0) | 311.1 (191.7–520.1) |
| Post-challenge glucose, mmol/l | 6.8 (5.5–8.2) | 6.6 (5.5–8.1) | 6.7 (5.4–8.1) | 6.8 (5.5–8.32) | 7.0 (5.6–8.8) |
| SBP, mmHg | 143 ± 19 | 143 ± 19 | 144 ± 19 | 143 ± 19 | 143 ± 19 |
| LDL-cholesterol, mmol/l | 3.3 (2.7–4.0) | 3.3 (2.7–3.9) | 3.4 (2.7–4.0) | 3.4 (2.7–4.0) | 3.3 (2.7–4.0) |
| HDL-cholesterol, mmol/l | 1.4 (1.1–1.7) | 1.4 (1.0–1.7) | 1.4 (1.1–1.7) | 1.4 (1.1–1.7) | 1.4 (1.2–1.7) |
| Diabetes | 165 (5.4) | 47 (6.2) | 38 (4.9) | 34 (4.4) | 46 (5.9) |
| No. of events (total mortality) | 282 (9.2) | 49 (6.4) | 66 (8.6) | 60 (7.8) | 104 (13.6) |
| GIPR rs1800437, MAF | 0.22 | 0.26 | 0.23 | 0.21 | 0.18 |
Values are expressed as mean ± SD, median (25th–75th interquartile range) or n (%)
MAF, minor allele frequency; Q1, quartile with the lowest values; Q4, quartile with the highest values